Cargando…
Comparison of Time to Report the Side Effects after AstraZeneca and Sinopharm Vaccinations in Users of the COVID-19 Symptom Study App: A Survey in South Iran
BACKGROUND: Concerns about the side effects of SARS-CoV-2 vaccines have been raised nationwide. We aimed to compare the time to report the side effects of the Oxford-AstraZeneca and Sinopharm COVID-19 vaccines. METHODS: Information on side effects of AstraZeneca and Sinopharm COVID-19 vaccines was o...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Iran University of Medical Sciences
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657253/ https://www.ncbi.nlm.nih.gov/pubmed/38021386 http://dx.doi.org/10.47176/mjiri.37.99 |
_version_ | 1785137175777509376 |
---|---|
author | Zare, Marjan Mirahmadizadeh, Alireza Khosravi, Masoumeh Karimi, Mohammadreza Dehghani, Seyedeh Leila |
author_facet | Zare, Marjan Mirahmadizadeh, Alireza Khosravi, Masoumeh Karimi, Mohammadreza Dehghani, Seyedeh Leila |
author_sort | Zare, Marjan |
collection | PubMed |
description | BACKGROUND: Concerns about the side effects of SARS-CoV-2 vaccines have been raised nationwide. We aimed to compare the time to report the side effects of the Oxford-AstraZeneca and Sinopharm COVID-19 vaccines. METHODS: Information on side effects of AstraZeneca and Sinopharm COVID-19 vaccines was obtained from the COVID-19 Symptom Study App affiliated with Shiraz University of Medical Science during 2021. A COX regression model with an adjusted Hazard Ratio and 95% Confidence Interval; HR (95% C.I) was reported at the significance level of < 0.05. RESULTS: 4478 and 5555 participants received the AstraZeneca and Sinopharm vaccines, respectively; more age, history of SARS-CoV-2 infection, first vaccine dose, hypertension, and hypertension with cardiovascular disease were seen in the AstraZeneca group (P < 0.05 for all). However, the AstraZeneca group had lower immune deficiency and time to report the side effects (P < 0.05 for both). There was significantly less time to pain HR(95% C.I.); 0.50 (0.47-0.52), vertigo 0.65 (0.61-0.69), weakness 0.41 (0.38-0.44), headache 0.43 (0.39-0.74), anorexia 0.31 (0.28-0.34), nausea 0.56 (0.51-0.62), severer allergy 0.71 (0.63-0.81), general inflammation 0.27 (0.23-0.31), fever > 38oC 0.12 (0.1-0.15), eye inflammation 0.45 (0.39-0.52), diarrhea 0.85 (0.73-0.99), blurred vision 0.73 (0.61-0.86), injection site redness 0.32 (0.26-0.39), fatigue/paleness 0.53 (0.50-0.57), joint pain 0.55 (0.41-0.73), auxiliary gland inflation 0.59 (0.43-0.80), convulsions 0.30 (0.17-0.52), and severe side effects 0.3 (0.27-0.33) in the AstraZeneca group; However, skin rash 0.77 (0.57-1.05) and hospitalization 0.72 (0.21-2.55) were the same. CONCLUSION: Sinopharm COVID-19 vaccine recipients reported longer times to report vaccine-related side effects than AstraZeneca; due to the lack of adverse effects like hospitalization, vaccination should continue to control the pandemic; more real-population studies are needed on the long-term effects of vaccination against COVID-19. |
format | Online Article Text |
id | pubmed-10657253 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Iran University of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-106572532023-09-12 Comparison of Time to Report the Side Effects after AstraZeneca and Sinopharm Vaccinations in Users of the COVID-19 Symptom Study App: A Survey in South Iran Zare, Marjan Mirahmadizadeh, Alireza Khosravi, Masoumeh Karimi, Mohammadreza Dehghani, Seyedeh Leila Med J Islam Repub Iran Original Article BACKGROUND: Concerns about the side effects of SARS-CoV-2 vaccines have been raised nationwide. We aimed to compare the time to report the side effects of the Oxford-AstraZeneca and Sinopharm COVID-19 vaccines. METHODS: Information on side effects of AstraZeneca and Sinopharm COVID-19 vaccines was obtained from the COVID-19 Symptom Study App affiliated with Shiraz University of Medical Science during 2021. A COX regression model with an adjusted Hazard Ratio and 95% Confidence Interval; HR (95% C.I) was reported at the significance level of < 0.05. RESULTS: 4478 and 5555 participants received the AstraZeneca and Sinopharm vaccines, respectively; more age, history of SARS-CoV-2 infection, first vaccine dose, hypertension, and hypertension with cardiovascular disease were seen in the AstraZeneca group (P < 0.05 for all). However, the AstraZeneca group had lower immune deficiency and time to report the side effects (P < 0.05 for both). There was significantly less time to pain HR(95% C.I.); 0.50 (0.47-0.52), vertigo 0.65 (0.61-0.69), weakness 0.41 (0.38-0.44), headache 0.43 (0.39-0.74), anorexia 0.31 (0.28-0.34), nausea 0.56 (0.51-0.62), severer allergy 0.71 (0.63-0.81), general inflammation 0.27 (0.23-0.31), fever > 38oC 0.12 (0.1-0.15), eye inflammation 0.45 (0.39-0.52), diarrhea 0.85 (0.73-0.99), blurred vision 0.73 (0.61-0.86), injection site redness 0.32 (0.26-0.39), fatigue/paleness 0.53 (0.50-0.57), joint pain 0.55 (0.41-0.73), auxiliary gland inflation 0.59 (0.43-0.80), convulsions 0.30 (0.17-0.52), and severe side effects 0.3 (0.27-0.33) in the AstraZeneca group; However, skin rash 0.77 (0.57-1.05) and hospitalization 0.72 (0.21-2.55) were the same. CONCLUSION: Sinopharm COVID-19 vaccine recipients reported longer times to report vaccine-related side effects than AstraZeneca; due to the lack of adverse effects like hospitalization, vaccination should continue to control the pandemic; more real-population studies are needed on the long-term effects of vaccination against COVID-19. Iran University of Medical Sciences 2023-09-12 /pmc/articles/PMC10657253/ /pubmed/38021386 http://dx.doi.org/10.47176/mjiri.37.99 Text en © 2023 Iran University of Medical Sciences https://creativecommons.org/licenses/by-nc-sa/1.0/This is an open-access article distributed under the terms of the Creative Commons Attribution NonCommercial-ShareAlike 1.0 License (CC BY-NC-SA 1.0), which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly. |
spellingShingle | Original Article Zare, Marjan Mirahmadizadeh, Alireza Khosravi, Masoumeh Karimi, Mohammadreza Dehghani, Seyedeh Leila Comparison of Time to Report the Side Effects after AstraZeneca and Sinopharm Vaccinations in Users of the COVID-19 Symptom Study App: A Survey in South Iran |
title | Comparison of Time to Report the Side Effects after AstraZeneca and Sinopharm
Vaccinations in Users of the COVID-19 Symptom Study App: A Survey in South Iran |
title_full | Comparison of Time to Report the Side Effects after AstraZeneca and Sinopharm
Vaccinations in Users of the COVID-19 Symptom Study App: A Survey in South Iran |
title_fullStr | Comparison of Time to Report the Side Effects after AstraZeneca and Sinopharm
Vaccinations in Users of the COVID-19 Symptom Study App: A Survey in South Iran |
title_full_unstemmed | Comparison of Time to Report the Side Effects after AstraZeneca and Sinopharm
Vaccinations in Users of the COVID-19 Symptom Study App: A Survey in South Iran |
title_short | Comparison of Time to Report the Side Effects after AstraZeneca and Sinopharm
Vaccinations in Users of the COVID-19 Symptom Study App: A Survey in South Iran |
title_sort | comparison of time to report the side effects after astrazeneca and sinopharm
vaccinations in users of the covid-19 symptom study app: a survey in south iran |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657253/ https://www.ncbi.nlm.nih.gov/pubmed/38021386 http://dx.doi.org/10.47176/mjiri.37.99 |
work_keys_str_mv | AT zaremarjan comparisonoftimetoreportthesideeffectsafterastrazenecaandsinopharmvaccinationsinusersofthecovid19symptomstudyappasurveyinsouthiran AT mirahmadizadehalireza comparisonoftimetoreportthesideeffectsafterastrazenecaandsinopharmvaccinationsinusersofthecovid19symptomstudyappasurveyinsouthiran AT khosravimasoumeh comparisonoftimetoreportthesideeffectsafterastrazenecaandsinopharmvaccinationsinusersofthecovid19symptomstudyappasurveyinsouthiran AT karimimohammadreza comparisonoftimetoreportthesideeffectsafterastrazenecaandsinopharmvaccinationsinusersofthecovid19symptomstudyappasurveyinsouthiran AT dehghaniseyedehleila comparisonoftimetoreportthesideeffectsafterastrazenecaandsinopharmvaccinationsinusersofthecovid19symptomstudyappasurveyinsouthiran |